Coherus BioSciences to Present at Bank of America Merrill Lynch Health Care Conference on May 11
May 04 2016 - 9:30AM
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play,
global biosimilars company with late-stage clinical products, today
announced that it will present at the Bank of America Merrill Lynch
Health Care Conference on Wednesday, May 11 at 9:20 am PT in Las
Vegas, Nevada.
A webcast of the presentation will be available on
the Investors page of the Coherus website at
http://investors.coherus.com.
About Coherus BioSciences,
Inc.
Coherus is a pure-play biosimilar platform company
that develops and commercializes high-quality therapeutics for
major regulated markets. Biosimilars are intended for use in place
of existing, branded biologics to treat a range of chronic and
often life-threatening diseases, with the potential to reduce costs
and expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production and clinical-regulatory
development, Coherus is positioned as a leader in the global
biosimilar marketplace. Coherus is advancing three late-stage
clinical products towards commercialization, CHS-1701
(pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and
CHS-1420 (adalimumab biosimilar), as well as developing a robust
pipeline of future products, including CHS-5217 (bevacizumab
biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional
information, please visit www.coherus.com.
CONTACT:
Keith Vendola, M.D.
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024